MDACC Study No:2012-0171LEUKEMIA ( NCT No: NCT01539291)
Title:A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS-1101) for Previously Treated Chronic Lymphocytic Leukemia
Principal Investigator:William G. Wierda
Treatment Agent:GS-1101; Rituximab
Study Status:Closed
Study Description:The goal of this clinical research study is to allow you to continue receiving
or start receiving idelalisib for as long as the study doctor thinks it is in
your best interest. This extension study will continue to study whether
idelalisib can help to control CLL. The long-term safety of this drug will
also continue to be studied.

Idelalisib is designed to block some of the cell functions that cause CLL cells
to grow and survive.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase III
Treatment Agents:GS-1101
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Gilead Sciences, Inc.
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
For Clinical Trial Enrollment:713-792-7543
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults